|
1
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Allemani C, Weir HK, Carreira H, Harewood
R, Spika D, Wang XS, Bannon F, Ahn JV, Johnson CJ, Bonaventure A,
et al CONCORD Working Group: Global surveillance of cancer survival
1995–2009: Analysis of individual data for 25,676,887 patients from
279 population-based registries in 67 countries (CONCORD-2).
Lancet. 385:977–1010. 2015. View Article : Google Scholar
|
|
3
|
Larsen JE and Minna JD: Molecular biology
of lung cancer: Clinical implications. Clin Chest Med. 32:703–740.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morgillo F, Kim WY, Kim ES, Ciardiello F,
Hong WK and Lee HY: Implication of the insulin-like growth
factor-IR pathway in the resistance of non-small cell lung cancer
cells to treatment with gefitinib. Clin Cancer Res. 13:2795–2803.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Del Vescovo V and Denti MA: microRNA and
lung cancer. Adv Exp Med Biol. 889:153–177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lagos-Quintana M, Rauhut R, Lendeckel W
and Tuschl T: Identification of novel genes coding for small
expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Del Vescovo V, Grasso M, Barbareschi M and
Denti MA: MicroRNAs as lung cancer biomarkers. World J Clin Oncol.
5:604–620. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee CT, Risom T and Strauss WM: MicroRNAs
in mammalian development. Birth Defects Res C Embryo Today.
78:129–139. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bueno MJ, Pérez de Castro I and Malumbres
M: Control of cell proliferation pathways by microRNAs. Cell Cycle.
7:3143–3148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jovanovic M and Hengartner MO: miRNAs and
apoptosis: RNAs to die for. Oncogene. 25:6176–6187. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mestdagh P, Hartmann N, Baeriswyl L,
Andreasen D, Bernard N, Chen C, Cheo D, D'Andrade P, DeMayo M,
Dennis L, et al: Evaluation of quantitative miRNA expression
platforms in the microRNA quality control (miRQC) study. Nat
Methods. 11:809–815. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Garofalo M, Quintavalle C, Di Leva G,
Zanca C, Romano G, Taccioli C, Liu CG, Croce CM and Condorelli G:
MicroRNA signatures of TRAIL resistance in human non-small cell
lung cancer. Oncogene. 27:3845–3855. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wong QW, Lung RW, Law PT, Lai PB, Chan KY,
To KF and Wong N: MicroRNA-223 is commonly repressed in
hepatocellular carcinoma and potentiates expression of Stathmin1.
Gastroenterology. 135:257–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao
QL, Wu W and Wu XZ: MiR-223 suppresses cell proliferation by
targeting IGF-1R. PLoS One. 6:e270082011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nian W, Ao X, Wu Y, Huang Y, Shao J, Wang
Y, Chen Z, Chen F and Wang D: miR-223 functions as a potent tumor
suppressor of the Lewis lung carcinoma cell line by targeting
insulin-like growth factor-1 receptor and cyclin-dependent kinase
2. Oncol Lett. 6:359–366. 2013.PubMed/NCBI
|
|
17
|
Peled N, Wynes MW, Ikeda N, Ohira T,
Yoshida K, Qian J, Ilouze M, Brenner R, Kato Y, Mascaux C and
Hirsch FR: Insulin-like growth factor-1 receptor (IGF-1R) as a
biomarker for resistance to the tyrosine kinase inhibitor gefitinib
in non-small cell lung cancer. Cell Oncol (Dordr). 36:277–288.
2013. View Article : Google Scholar
|
|
18
|
Baserga R, Peruzzi F and Reiss K: The
IGF-1 receptor in cancer biology. Int J Cancer. 107:873–877. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pollak MN, Schernhammer ES and Hankinson
SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer.
4:505–518. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang Q, Zhao DY, Xu H, Zhou H, Yang QY,
Liu F and Zhou GP: Downregulation of microRNA-223 promotes
degranulation via the PI3K/Akt pathway by targeting IGF-1R in mast
cells. PLoS One. 10:e01235752015. View Article : Google Scholar
|
|
21
|
Yuan Y, Shen Y, Xue L and Fan H: miR-140
suppresses tumor growth and metastasis of non-small cell lung
cancer by targeting insulin-like growth factor 1 receptor. PLoS
One. 8:e736042013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Agulló-Ortuño MT, Díaz-García CV,
Agudo-López A, Pérez C, Cortijo A, Paz-Ares L, López-Ríos F, Pozo
F, de Castro J and López Martín JA: Relevance of insulin-like
growth factor 1 receptor gene expression as a prognostic factor in
non-small-cell lung cancer. J Cancer Res Clin Oncol. 141:43–53.
2015. View Article : Google Scholar
|
|
23
|
Scherr M, Venturini L and Eder M:
Lentiviral vector-mediated expression of pre-miRNAs and antagomiRs.
Methods Mol Biol. 614:175–185. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ryan BM, Robles AI and Harris CC: Genetic
variation in microRNA networks: The implications for cancer
research. Nat Rev Cancer. 10:389–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen CZ, Li L, Lodish HF and Bartel DP:
MicroRNAs modulate hematopoietic lineage differentiation. Science.
303:83–86. 2004. View Article : Google Scholar
|
|
26
|
Yang W, Lan X, Li D, Li T and Lu S:
MiR-223 targeting MAFB suppresses proliferation and migration of
nasopharyngeal carcinoma cells. BMC Cancer. 15:4612015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu YH, Zhang L, Wu DS, Zhang Z, Huang FF,
Zhang J, Chen XP, Liang DS, Zeng H and Chen FP: MiR-223 regulates
human embryonic stem cell differentiation by targeting the
IGF-1R/Akt signaling pathway. PLoS One. 8:e787692013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sanfiorenzo C, Ilie MI, Belaid A, Barlési
F, Mouroux J, Marquette CH, Brest P and Hofman P: Two panels of
plasma microRNAs as non-invasive biomarkers for prediction of
recurrence in resectable NSCLC. PLoS One. 8:e545962013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Heegaard NH, Schetter AJ, Welsh JA, Yoneda
M, Bowman ED and Harris CC: Circulating micro-RNA expression
profiles in early stage nonsmall cell lung cancer. Int J Cancer.
130:1378–1386. 2012. View Article : Google Scholar
|
|
30
|
Yamasaki F, Johansen MJ, Zhang D,
Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K,
Mills GB, Hortobagyi GN and Ueno NT: Acquired resistance to
erlotinib in A-431 epidermoid cancer cells requires downregulation
of MMAC1/PTEN and upregulation of phosphorylated Akt. Cancer Res.
67:5779–5788. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bohula EA, Playford MP and Macaulay VM:
Targeting the type 1 insulin-like growth factor receptor as
anti-cancer treatment. Anticancer Drugs. 14:669–682. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Scartozzi M, Bianconi M, Maccaroni E,
Giampieri R, Berardi R and Cascinu S: Dalotuzumab, a recombinant
humanized mAb targeted against IGFR1 for the treatment of cancer.
Curr Opin Mol Ther. 12:361–371. 2010.PubMed/NCBI
|
|
33
|
Reidy-Lagunes DL, Vakiani E, Segal MF,
Hollywood EM, Tang LH, Solit DB, Pietanza MC, Capanu M and Saltz
LB: A phase 2 study of the insulin-like growth factor-1 receptor
inhibitor MK-0646 in patients with metastatic, well-differentiated
neuro-endocrine tumors. Cancer. 118:4795–4800. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pollak M: Insulin and insulin-like growth
factor signalling in neoplasia. Nat Rev Cancer. 8:915–928. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jameson MJ, Beckler AD, Taniguchi LE,
Allak A, Vanwagner LB, Lee NG, Thomsen WC, Hubbard MA and Thomas
CY: Activation of the insulin-like growth factor-1 receptor induces
resistance to epidermal growth factor receptor antagonism in head
and neck squamous carcinoma cells. Mol Cancer Ther. 10:2124–2134.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kavran JM, McCabe JM, Byrne PO, Connacher
MK, Wang Z, Ramek A, Sarabipour S, Shan Y, Shaw DE, Hristova K, et
al: How IGF-1 activates its receptor. Elife. 3:32014. View Article : Google Scholar
|
|
37
|
Brahmkhatri VP, Prasanna C and Atreya HS:
Insulin-like growth factor system in cancer: Novel targeted
therapies. BioMed Res Int. 2015:5380192015. View Article : Google Scholar : PubMed/NCBI
|
